Clinical trial · Interventional
Incremental Value of Magnetic Resonance Imaging in Selection of Pancreatic Cancer Patients for Surgery
Incremental Value of Magnetic Resonance Imaging in Selection of Pancreatic Cancer Patients for Surgery (MAGIPAC): A Randomized Clinical Trial.
NCT05428358CI-TRIAL-00109810MAGIPACrecruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of the study is to examine the incremental value of using magnetic resonance imaging (MRI) in addition to computed tomography (CT) in the diagnostic workup of pancreatic cancer patients.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Liver Metastases | — | UNRESOLVED | — |
| Pancreatic Cancer | Malignant Pancreatic Neoplasm | CURATED_EXACT | 0.92 |
| Pancreatic Neoplasm | Pancreatic Neoplasm | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Preoperative MRI | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Preoperative MRI
- description
- MRI before surgery.
- interventionNames
- Diagnostic Test: Preoperative MRI
Primary outcomes (1)
- measure
- Change in treatment strategy
- timeFrame
- 1 week
- description
- Change in treatment strategy from intended curative resection to other treatment based on MRI scan
Secondary outcomes (8)
- measure
- Liver metastases
- timeFrame
- 1 week
- description
- Proportion of patients who had liver metastases detected on MRI
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 99 Years
Show eligibility criteria text
Inclusion criteria: * Pancreatic cancer patients considered to have a locally resectable or borderline resectable tumor by the local hepato-pancreato-biliary multidisciplinary team board * No liver metastases on CT * At least 18 years old and able to provide informed consent * Expected pancreatic ductal adenocarcinoma based on CT scan Exclusion criteria: * Metastatic disease * Prior receipt of neoadjuvant chemotherapy or downstaging/-sizing treatment * Comorbidity rendering major surgery unfeasible (inoperable) * No informed consent * Unable to undergo MRI (Kidney insufficiency (eGFR \< 60 ml/min/1.73 m2 body surface ar-ea); Claustrophobia; Cardiac pacemaker) * Postoperative histology other than adenocarcinoma of pancreato-biliary origin. * MRI with liver-specific contrast performed during standard workup.
References
Publications (0)
Data not yet available
No reference posted for this study.